Site Under Development, Content Population and SEO, Soft Launch 1st January 2020

  Nov 22, 2018
CLIA Waived Molecular Rapid Flu Test from Alere.
CLIA Waived Molecular Rapid Flu Test from Alere.
  Nov 22, 2018

The Alere™ i Influenza A & B test revolutionizes rapid flu testing by providing highly accurate, molecular results in less than 15 minutes on the user-friendly Alere™ i platform. A rapid, molecular flu result with Alere™ i Influenza A & B empowers you to transform patient care in any setting.

Alere i Influenza A & B

  • Gives you confidence to make appropriate clinical decisions sooner
  • Enables prompt initiation of infection control measures
  • Aids targeted antiviral therapy and Antimicrobial Stewardship
  • Allows you to respond quickly and accurately in any setting
  • With a positive result, you can test and treat in a single patient visit

Outstanding Performance

Alere i Influenza A & B vs. PCR

   PPA: Positive Percent Agreement
    NPA: Negative Percent Agreement

Alere i Influenza A & B Performance vs. Culture

   a. Flu A nucleic acid was detected in 58/66 False Positive specimens using an FDA-cleared molecular test.
   b. Flu A nucleic acid was not detected in 1/2 False Negative specimens using an FDA-cleared molecular test.
   c. Flu B nucleic acid was detected in 15/17 False Positive specimens using an FDA-cleared molecular test.
   d. Flu B nucleic acid was not detected in 4/6 False Negative specimens using an FDA-cleared molecular test.

A new level of confidence in test sensitivity²,³

Faster than other molecular methods

The Alere™ i Influenza A & B kit contains all components required to carry out an assay for influenza A and B on the Alere™ i instrument. It tests for the qualitative detection and differentiation of influenza A and influenza B from nasal swab samples and viral transport media.

For more detail: https://www.news-medical.net/ads/abmc.aspx?b=1918

Request a Quote
for CLIA Waived Molecular Rapid Flu Test from Alere.